vimarsana.com
Home
Live Updates
Dabrafenib and Trametinib Plus Navitoclax Meets CR End Point in BRAF V600–mutant Metastatic Melanoma : vimarsana.com
Dabrafenib and Trametinib Plus Navitoclax Meets CR End Point in BRAF V600–mutant Metastatic Melanoma : vimarsana.com
Dabrafenib and Trametinib Plus Navitoclax Meets CR End Point in BRAF V600–mutant Metastatic Melanoma
The combination of dabrafenib and trametinib plus navitoclax generated responses and met the co-primary end point for complete response rate vs historical controls in patients with BRAF V600–mutant metastatic melanoma.
Related Keywords
Florida ,
United States ,
Tampa ,
Anita Giobbie Hurder ,
Zeynep Eroglu ,
Genentech Roche ,
Elsevier ,
Novartis ,
Boehringer Ingelheim ,
Pfizer ,
Department Of Oncologic Sciences ,
Cutaneous Oncology ,
Moffitt Cancer Center ,
Oncologic Sciences ,
South Florida Morsani College ,
Dabrafenib ,
Navitoclax ,
Trametinib ,
Melanoma ,
Asco Annual Meeting ,
Nct01989585 ,
Ctep P9466 ,